NZ517631A - Formulations for parenteral use of estramustine phosphate with improved pharmacological properties - Google Patents

Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Info

Publication number
NZ517631A
NZ517631A NZ517631A NZ51763100A NZ517631A NZ 517631 A NZ517631 A NZ 517631A NZ 517631 A NZ517631 A NZ 517631A NZ 51763100 A NZ51763100 A NZ 51763100A NZ 517631 A NZ517631 A NZ 517631A
Authority
NZ
New Zealand
Prior art keywords
estramustine phosphate
cyclodextrin
human albumin
formulation
cancer
Prior art date
Application number
NZ517631A
Other languages
English (en)
Inventor
Alessandro Martini
Giovanni Buzzi
Lorena Muggetti
Paolo Colombo
Original Assignee
Pharmacia Italia S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S filed Critical Pharmacia Italia S
Publication of NZ517631A publication Critical patent/NZ517631A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ517631A 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties NZ517631A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921954.5A GB9921954D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
PCT/EP2000/007679 WO2001019338A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Publications (1)

Publication Number Publication Date
NZ517631A true NZ517631A (en) 2004-01-30

Family

ID=10861066

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ517631A NZ517631A (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Country Status (20)

Country Link
EP (1) EP1212040A1 (ja)
JP (1) JP2003509355A (ja)
KR (1) KR20020059405A (ja)
CN (1) CN1177583C (ja)
AU (1) AU777763B2 (ja)
BR (1) BR0014063A (ja)
CA (1) CA2385063A1 (ja)
CZ (1) CZ2002943A3 (ja)
EA (1) EA005308B1 (ja)
GB (1) GB9921954D0 (ja)
HK (1) HK1047227A1 (ja)
HU (1) HUP0202621A2 (ja)
IL (1) IL148409A0 (ja)
MX (1) MXPA02002859A (ja)
NO (1) NO20021306L (ja)
NZ (1) NZ517631A (ja)
PL (1) PL353954A1 (ja)
SK (1) SK3452002A3 (ja)
WO (1) WO2001019338A1 (ja)
ZA (1) ZA200201743B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
EP2620023B1 (en) 2010-09-21 2018-02-28 Telefonaktiebolaget LM Ericsson (publ) Air-interface timing synchronization sharing
WO2019094819A2 (en) * 2017-11-09 2019-05-16 Abon Pharmaceuticals, Llc Intravenous delivery systems for chemotherapy drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (ja) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
GB9419153D0 (en) * 1994-09-22 1994-11-09 Erba Carlo Spa Estramustine formulations with improved pharmaceutical properties
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
AU777763B2 (en) 2004-10-28
CN1374858A (zh) 2002-10-16
CN1177583C (zh) 2004-12-01
HUP0202621A2 (hu) 2002-12-28
WO2001019338A1 (en) 2001-03-22
EA200200369A1 (ru) 2002-08-29
EP1212040A1 (en) 2002-06-12
AU6836300A (en) 2001-04-17
SK3452002A3 (en) 2002-08-06
ZA200201743B (en) 2003-05-28
CZ2002943A3 (cs) 2002-08-14
JP2003509355A (ja) 2003-03-11
NO20021306D0 (no) 2002-03-15
KR20020059405A (ko) 2002-07-12
GB9921954D0 (en) 1999-11-17
IL148409A0 (en) 2002-09-12
CA2385063A1 (en) 2001-03-22
MXPA02002859A (es) 2003-07-21
EA005308B1 (ru) 2004-12-30
NO20021306L (no) 2002-04-24
BR0014063A (pt) 2004-06-29
HK1047227A1 (zh) 2003-02-14
PL353954A1 (en) 2003-12-15

Similar Documents

Publication Publication Date Title
EP1214078B1 (en) Formulations for parenteral use of estramustine phosphate and amino acids
US6730664B1 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
NZ517632A (en) Formulations for parenteral use of estramustine phosphate and albumin
AU777763B2 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
ZA200201955B (en) Formulations for parenteral use of estramustine phosphate and albumin.
ITMI991998A1 (it) Formulazioni di estramustina fosfato ed albumina per uso parenterale

Legal Events

Date Code Title Description
S23 Proceedings under section 23: mention of inventor as such in patent

Inventor name: GIOVANNI BUZZI

Inventor name: ALESSANDRO MARTINI

Inventor name: PAOLO COLOMBO

Inventor name: LORENA MUGGETTI

PSEA Patent sealed
RENW Renewal (renewal fees accepted)